Iterum Therapeutics PLC to Post Q3 2019 Earnings of ($1.75) Per Share, Svb Leerink Forecasts (NASDAQ:ITRM)

Iterum Therapeutics PLC (NASDAQ:ITRM) – Investment analysts at Svb Leerink lowered their Q3 2019 earnings per share (EPS) estimates for shares of Iterum Therapeutics in a note issued to investors on Thursday, August 15th. Svb Leerink analyst A. Fadia now expects that the company will earn ($1.75) per share for the quarter, down from their prior estimate of ($1.63). Svb Leerink also issued estimates for Iterum Therapeutics’ Q4 2019 earnings at ($0.98) EPS, FY2019 earnings at ($6.10) EPS, FY2020 earnings at ($2.24) EPS, FY2021 earnings at ($1.86) EPS, FY2022 earnings at ($0.73) EPS and FY2023 earnings at $0.47 EPS.

Iterum Therapeutics (NASDAQ:ITRM) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.50) by ($0.43). Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 136.21%.

ITRM has been the topic of several other reports. Royal Bank of Canada cut their target price on Iterum Therapeutics to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th. Zacks Investment Research raised Iterum Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Iterum Therapeutics in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $15.75.

NASDAQ ITRM opened at $6.70 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.10 and a quick ratio of 2.10. The stock has a market capitalization of $94.36 million, a PE ratio of -0.94 and a beta of 2.05. Iterum Therapeutics has a 1 year low of $4.70 and a 1 year high of $11.22. The business’s 50-day moving average is $6.65 and its 200 day moving average is $6.84.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

See Also: What are municipal bonds?

Earnings History and Estimates for Iterum Therapeutics (NASDAQ:ITRM)

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.